cisplatinum VAC end stage squamous cell carcinoma head neck Sixteen patients end stage squamous cell carcinoma head neck phase II study courses cisplatinum VAC vincristine weekly intervals patients response cent median survival time days similar group patients chemotherapy previous trial days 